X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to conduct a proof-of-concept study in a genetically selected sub-population of high-grade serous ovarian cancer. Esperas is developing the first oral Check 1 inhibitor, ESP-001 with the potential to treat certain types of cancers including HGSOC.
Lead Product(s): ESP-001,Gemcitabine
Therapeutic Area: Oncology Product Name: ESP-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TVM Capital Life Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 21, 2023
Details:
Recurv Pharma will use the funding in the development of a novel taxane therapy, RP-001, therapy to treat solid tumors. RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing healthy organs.
Lead Product(s): RP-001
Therapeutic Area: Oncology Product Name: RP-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Recurv Pharma
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
